Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 1998

View Archived Issues

Preliminary clinical efficacy demonstrated for PDE III inhibitor in asthma

Takeda establishes European subsidiary

PPL's AAT granted orphan drug status by FDA

Anergen files IND for AnergiX

Positive trial results reported for AlloDerm

Calcium channel blockers do not increase risk of cancer in patients with coronary artery disease

Beneficial effects of warfarin in patients with cardiac disorders

French researchers describe novel antinociceptive agent

First selective 5-HT7 receptor antagonist reported

P-gp as a complicating factor in childhood rheumatic diseases

Lilly describes PAI-1-inhibitory benzothiophenes with cardioprotective effects

Clinical efficacy demonstrated for rhuMAb-E25 in asthma

Prenyl transferase inhibitors from Biomeasure

BMS prepares new paclitaxel analogues

Merck & Co. research leads to new fibrinogen receptor antagonist prodrugs

Banyu isolates new antibacterial compounds from Microtetraspora sp.

Jak-2 inhibitor indicated for control of allergic inflammation

Mitsui Toatsu prepares new thymidine phosphorylase inhibitors

GenQuest offers prostate cancer-related genes for licensing

GenQuest offers antibodies and related technology for licensing

Mda genes and platform technology available for licensing from GenQuest

Gene discovery technologies available for licensing from GenQuest

Epi-2010, a novel antisense oligonucleotide for asthma

AD-related technology available for licensing

Phase I dose escalation study of MS-325 complete

Pacific Pharmaceuticals in-licenses cancer chemosensitizer

NaPro and Ivax terminate paclitaxel agreement

Prosaptide TX14(A) shows promise in phase I

T7T7 increases efficacy of cancer gene therapy in preclinical studies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...